Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim Portfolio News / Karina Tin November 29, 2022 Ribon Therapeutics Announces Acquisition of Pre-Clinical CD38 Program by Boehringer Ingelheim Read More »
Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration Portfolio News / Karina Tin November 29, 2022 Cajal Neuroscience Launches with $96 Million to Transform Target and Drug Discovery in Neurodegeneration Read More »
Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy Portfolio News / Karina Tin November 28, 2022 Tenaya Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for its Gene Therapy for Genetic Arrhythmogenic Right Ventricular Cardiomyopathy Read More »
Escient Pharmaceuticals Announces $120 Million Series C Financing Portfolio News / Karina Tin November 28, 2022 Escient Pharmaceuticals Announces $120 Million Series C Financing Read More »
Tenaya Therapeutics Announces Closing of Public Offering Portfolio News / Karina Tin November 21, 2022 Tenaya Therapeutics Announces Closing of Public Offering Read More »
Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data Portfolio News / Karina Tin November 21, 2022 Neurona Therapeutics Presents Encouraging Clinical Data from First-Ever Regenerative Human Cell Therapy Trial in Adults with Drug-Resistant Focal Epilepsy and Shows Supporting Manufacturing, Delivery, and Preclinical Data Read More »
Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus Portfolio News / Karina Tin November 17, 2022 Escient Pharmaceuticals Initiates Phase 2 Pacific Study Evaluating EP547, an Oral MRGPRX4 Antagonist, in Subjects with Cholestatic Pruritus Read More »
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Portfolio News / Karina Tin November 17, 2022 RAPT Therapeutics Announces Pricing of Public Offering of Common Stock Read More »
Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires Portfolio News / Karina Tin November 16, 2022 Escient Pharmaceuticals Strengthens Leadership Team with Key New Hires Read More »
Casma Therapeutics Raises $46.0 M in Series C Funding Portfolio News / Karina Tin November 15, 2022 Casma Therapeutics Raises $46.0 M in Series C Funding Read More »
